Volker Pönitz

Dr. Volker Pönitz


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2009 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
VPVolker Pönitz
Volker Pönitz
TBT. Brügger‐Andersen
T. Brügger‐Andersen
DPD. Pritchard
D. Pritchard
HGH. Grundt
H. Grundt
HSH. Staines
H. Staines
DND. W. T. Nilsen
D. W. T. Nilsen

25 November 2008 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
TBTrygve Brügger-Andersen
Trygve Brügger-Andersen
VPVolker Pönitz
Volker Pönitz
HSHarry Staines
Harry Staines
DPDavid Pritchard
David Pritchard
HGHeidi Grundt
Heidi Grundt
DNDennis Wt Nilsen
Dennis Wt Nilsen
Few studies have addressed whether the combined use of B-type natriuretic peptide (BNP) and high-sensitive C-reactive protein (hsCRP) improves risk stratification for mortality and cardiovascular events in a population with chest pain and suspected acute coronary syndromes (ACS). Therefore, we wanted to assess the incremental prognostic value of these biomarkers with respect to long-term all-cause mortality and recurrent troponin T (TnT) positive cardiac events in 871 patients admitted to the emergency department.

17 November 2006 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
VPVolker Pönitz
Volker Pönitz
DPDavid Pritchard
David Pritchard
HGHeidi Grundt
Heidi Grundt
DNDennis Winston T. Nilsen
Dennis Winston T. Nilsen

1 July 2009 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
VPVolker Pönitz
Volker Pönitz
JGJ. W. P. Govers‐Riemslag
J. W. P. Govers‐Riemslag
TBT. Brügger‐Andersen
T. Brügger‐Andersen
HCH. Ten Cate
H. Ten Cate
DND. W. T. Nilsen
D. W. T. Nilsen

11 May 2007 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
VPVolker Pönitz
Volker Pönitz
DPDavid Pritchard
David Pritchard
HGHeidi Grundt
Heidi Grundt
MMMai-Britt Mehus
Mai-Britt Mehus
DNDennis Winston T. Nilsen
Dennis Winston T. Nilsen

1 December 2009 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Closed access
VPVolker Pönitz
Volker Pönitz
TBTrygve Brügger-Andersen
Trygve Brügger-Andersen
DPDavid Pritchard
David Pritchard
HGHeidi Grundt
Heidi Grundt
HSHarry Staines
Harry Staines
DNDennis Wt Nilsen
Dennis Wt Nilsen
The aim of this analysis was to assess the predictive value of activated factor XII type A (XIIaA) and B-type natriuretic peptide (BNP) in acute coronary syndrome patients stratified according to troponin release and to evaluate their complementary utility as predictors of all-cause mortality and recurrent troponin T (TnT)-positive events. Multivariable analysis in 870 patients admitted with suspected myocardial infarction was performed using the Cox proportional hazard ratio model. Variables in the model included XIIaA and BNP as well as conventional risk factors for mortality. Although both XIIaA and BNP were identified as independent predictors for all-cause mortality in the total group of patients, only BNP was found to be an independent predictor for all-cause mortality in patients with a confirmed myocardial infarction (TnT > 0.05 ng/ml) at admission (hazard ratio 4.24, 95% confidence interval 1.28-14.07), whereas only XIIaA was an independent predictor for all-cause mortality in patients with low TnT release (0.01 < TnT < or = 0.05 ng/ml) at admission (hazard ratio 10.37, 95% confidence interval 2.89-37.21). The combination of these two biomarkers provided complementary prognostic information for all-cause mortality as compared with each of the biomarkers alone in the total patient material. XIIaA is particularly useful in predicting mortality in acute coronary syndrome patients with low troponin release, whereas BNP is effective in predicting mortality in patients with confirmed myocardial infarction and more substantial troponin release. The combination of these two biomarkers improves outcome prediction in unselected patients with chest pain and acute coronary syndrome.